4.50k followers • 19 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Accuray (ARAY) delivered earnings and revenue surprises of 75.00% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Cannabis Updates: New Listings, Price Action, and RatingsCannabis updateThe cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking at Bristol-Myers Squibb Company's (NYSE:BMY) earnings update in December 2018, analyst consensus outlook appear cautiously optimistic, with earnings expected to grow by...
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
In a series of filings concerning the Pennsylvania-based bank over the past week, activists CT Opportunity Management and Driver Management disclosed that they had submitted proposed terms on March 23. The activist investors, filing together on April 4, reported that DNB Financial had declined to accept the term sheet.